JP6678571B2 - 高薬物含有ブプレノルフィンマイクロスフェア及びその製造方法 - Google Patents

高薬物含有ブプレノルフィンマイクロスフェア及びその製造方法 Download PDF

Info

Publication number
JP6678571B2
JP6678571B2 JP2016502675A JP2016502675A JP6678571B2 JP 6678571 B2 JP6678571 B2 JP 6678571B2 JP 2016502675 A JP2016502675 A JP 2016502675A JP 2016502675 A JP2016502675 A JP 2016502675A JP 6678571 B2 JP6678571 B2 JP 6678571B2
Authority
JP
Japan
Prior art keywords
buprenorphine
solvent
phase
dispersed phase
release
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016502675A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016513721A5 (https=
JP2016513721A (ja
Inventor
リッチー，トレイシー
タノー，バガバシカヌン，チサンバラ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of JP2016513721A publication Critical patent/JP2016513721A/ja
Publication of JP2016513721A5 publication Critical patent/JP2016513721A5/ja
Application granted granted Critical
Publication of JP6678571B2 publication Critical patent/JP6678571B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5089—Processes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2016502675A 2013-03-15 2014-03-14 高薬物含有ブプレノルフィンマイクロスフェア及びその製造方法 Active JP6678571B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13/837,181 US9393211B2 (en) 2013-03-15 2013-03-15 High drug load buprenorphine microspheres and method of producing same
US13/837,181 2013-03-15
PCT/US2014/027982 WO2014143839A1 (en) 2013-03-15 2014-03-14 High drug load buprenorphine microspheres and method of producing the same

Publications (3)

Publication Number Publication Date
JP2016513721A JP2016513721A (ja) 2016-05-16
JP2016513721A5 JP2016513721A5 (https=) 2017-04-20
JP6678571B2 true JP6678571B2 (ja) 2020-04-08

Family

ID=51528078

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016502675A Active JP6678571B2 (ja) 2013-03-15 2014-03-14 高薬物含有ブプレノルフィンマイクロスフェア及びその製造方法

Country Status (9)

Country Link
US (1) US9393211B2 (https=)
EP (1) EP2968577B1 (https=)
JP (1) JP6678571B2 (https=)
CN (1) CN105377301B (https=)
BR (1) BR112015022985A2 (https=)
CA (1) CA2904432A1 (https=)
ES (1) ES2717942T3 (https=)
MX (1) MX362709B (https=)
WO (1) WO2014143839A1 (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8852638B2 (en) 2005-09-30 2014-10-07 Durect Corporation Sustained release small molecule drug formulation
EP2152315B1 (en) 2007-05-25 2016-01-06 Indivior UK Limited Sustained delivery formulations of risperidone compounds
US9272044B2 (en) 2010-06-08 2016-03-01 Indivior Uk Limited Injectable flowable composition buprenorphine
GB2481017B (en) 2010-06-08 2015-01-07 Rb Pharmaceuticals Ltd Microparticle buprenorphine suspension
NZ704012A (en) 2012-07-26 2017-09-29 Camurus Ab Opioid formulations
EP3791861A1 (en) 2012-07-26 2021-03-17 Camurus AB Opioid formulations
US9636308B2 (en) * 2013-03-15 2017-05-02 Oakwood Laboratories LLC High drug load buprenorphine microspheres and method of producing same
GB201404139D0 (en) 2014-03-10 2014-04-23 Rb Pharmaceuticals Ltd Sustained release buprenorphine solution formulations
EP3141241A1 (en) * 2015-09-08 2017-03-15 Andreas Voigt Sustained release low dose formulations and uses thereof
CN105596298B (zh) * 2015-12-18 2018-08-14 山东大学 一种包载丁丙诺啡的peg-plga缓释微球及其制备方法
EP3419596A1 (en) * 2016-02-23 2019-01-02 BioDelivery Sciences International, Inc. Sustained release buprenorphine microspheres (srbm) and methods of use thereof
TWI743193B (zh) 2016-09-13 2021-10-21 昱展新藥生技股份有限公司 丁基原啡因緩釋製劑
BR112020016576A2 (pt) 2018-05-11 2020-12-15 Alar Pharmaceuticals Inc. Formulações injetáveis de ação prolongada e formas cristalinas de derivados de buprenorfina
US12433841B2 (en) 2020-02-26 2025-10-07 Fordoz Pharma Corp. Injectable controlled-release formulations of progestogen drugs
US11992559B2 (en) 2021-02-24 2024-05-28 Oakwood Laboratories, Llc Microsphere formulations comprising lurasidone and methods for making and using the same
CN114392384B (zh) * 2021-12-24 2023-04-11 河南驼人医疗器械研究院有限公司 一种制备高载药量栓塞微球的方法及收集装置
CN115317453A (zh) * 2022-09-01 2022-11-11 广东嘉博制药有限公司 一种缓释微球制剂及其制备方法与用途
CN120152701A (zh) * 2022-10-31 2025-06-13 奥克伍德实验室有限责任公司 包含奥曲肽的混合释放曲线聚合物微球制剂及其制备和使用方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5026556A (en) * 1988-11-10 1991-06-25 Norwich Eaton Pharmaceuticals, Inc. Compositions for the transdermal delivery of pharmaceutical actives
EP1555023A3 (en) * 1999-08-27 2005-09-28 Southern Research Institute Injectable buprenorphine microparticle compositions and their use
RO121631B1 (ro) * 1999-08-27 2008-01-30 Southern Research Institute Compoziţie cu buprenorfină şi utilizarea acesteia pentru reducerea consumului de heroină şi/sau alcool
US7041320B1 (en) 2002-05-31 2006-05-09 Biotek, Inc. High drug loaded injectable microparticle compositions and methods of treating opioid drug dependence
US20050048115A1 (en) 2003-08-27 2005-03-03 Murty Mangena Buprenorphine microspheres
TWI362947B (en) * 2007-03-08 2012-05-01 Univ Kaohsiung Medical Controlled release pharmaceutical composition and manufacture method thereof
US9161943B2 (en) 2007-12-31 2015-10-20 Industrial Technology Research Institute Sustained release composition and manufacturing method thereof
KR101113044B1 (ko) * 2008-08-29 2012-02-27 동국제약 주식회사 용매교류증발법에 의한 서방출성 미립구의 제조방법
US20100086597A1 (en) 2008-10-06 2010-04-08 Oakwood Laboratories LLC Microspheres for the sustained release of octreotide with a low initial burst
WO2011087496A1 (en) 2010-01-13 2011-07-21 Oakwood Laboratories LLC Microspheres for the sustained release of octreotide without an initial time lag
GB2481018B (en) 2010-06-08 2015-03-18 Rb Pharmaceuticals Ltd Injectable flowable composition comprising buprenorphine

Also Published As

Publication number Publication date
CN105377301B (zh) 2020-06-05
MX2015012232A (es) 2015-12-01
CN105377301A (zh) 2016-03-02
US9393211B2 (en) 2016-07-19
ES2717942T3 (es) 2019-06-26
US20140271869A1 (en) 2014-09-18
MX362709B (es) 2019-02-05
EP2968577A1 (en) 2016-01-20
EP2968577A4 (en) 2016-11-23
BR112015022985A2 (pt) 2017-08-22
CA2904432A1 (en) 2014-09-18
WO2014143839A1 (en) 2014-09-18
JP2016513721A (ja) 2016-05-16
EP2968577B1 (en) 2019-01-02

Similar Documents

Publication Publication Date Title
JP6678571B2 (ja) 高薬物含有ブプレノルフィンマイクロスフェア及びその製造方法
JP7038741B2 (ja) 放出制御が容易な徐放性薬物微粒子の製造方法
JP2016513721A5 (https=)
US9636308B2 (en) High drug load buprenorphine microspheres and method of producing same
JP6249584B2 (ja) 薬物含有徐放性微粒子の製造方法
CN115942935B (zh) 包括氯胺酮的微球制剂及其制备和使用方法
WO2022198167A1 (en) Microsphere formulations comprising naltrexone and methods for making and using the same
US11992559B2 (en) Microsphere formulations comprising lurasidone and methods for making and using the same
US20240216280A1 (en) Microsphere formulations comprising nalmefene andmethods for making and using the same
US20250032451A1 (en) Microsphere formulations comprising asenapine and methods for making and using the same
US20230225993A1 (en) Microsphere formulations comprising ketamine and methods for making and using the same
JP2026507990A (ja) オクトレオチドを含む混合放出プロファイルポリマーミクロスフェア製剤ならびにその製造方法及び使用方法
US20240307381A1 (en) Microsphere formulations comprising lurasidone and methods for making and using the same
WO2025117624A1 (en) Microsphere formulations comprising brexpiprazole and methods for making and using the same
WO2023133554A2 (en) Microsphere formulations comprising ketamine and methods for making and using the same
CN116916893A (zh) 包含btk抑制剂的微球制剂及其制备和使用方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170314

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170314

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20171129

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180228

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180313

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180905

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20181204

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190131

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190304

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190807

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20191106

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191218

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200205

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200221

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20200311

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20200317

R150 Certificate of patent or registration of utility model

Ref document number: 6678571

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250